AbbVie Details Phase 3 TrenibotE Safety and 8-Hour Efficacy
An 18-week open-label Phase 3 trial of AbbVie’s neurotoxin TrenibotE showed consistent safety over three treatments, no neutralizing antibodies and glabellar-line reduction in eight hours. GLP-1 patient surveys show 52% report facial concerns, 32% are new to aesthetics, with cost (82%) and fear of unnatural results (58%) as barriers.
1. Phase 3 Trial Results
The 18-week open-label Phase 3 study evaluated up to three TrenibotE treatments in glabellar lines, demonstrating no neutralizing antibody development, consistent safety across sequences and rapid severity reduction noted within eight hours of administration.
2. TrenibotE Product Profile
TrenibotE is a first-in-class botulinum neurotoxin serotype E with rapid onset at the earliest eight-hour assessment and a 2–3 week duration, offering a differentiated profile from existing products pending approval.
3. GLP-1 Patient Aesthetic Behaviors
A survey of aesthetics clinics treating GLP-1 agonist patients revealed that 52% express facial concerns during weight-loss therapy, 32% are new to aesthetic services, and 82% and 58% cite cost and fear of unnatural outcomes as barriers, respectively.